Device type · MZO
Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
MZO
Microbiology
Device class
Class II
FDA decisions since 2015
5
510(k), De Novo and PMA
Adverse event reports
126
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
- Product code
- MZO
- Device class
- Class II
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3169
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for MZO
Latest FDA decisions
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- Anti-HCV Next510(k)
K252424 · Decided Apr 28, 2026 · 270 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
K221693 · Decided Jan 4, 2023 · 208 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Reports received
126
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
124
98% of reports
Injury reports
2
1.6% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 2 | 1 | 0 | 0 |
| Jan 24 | 5 | 0 | 0 | 0 |
| Feb 24 | 2 | 0 | 0 | 0 |
| Mar 24 | 6 | 0 | 0 | 0 |
| Apr 24 | 8 | 0 | 0 | 0 |
| May 24 | 6 | 0 | 0 | 0 |
| Jun 24 | 4 | 0 | 0 | 0 |
| Jul 24 | 6 | 0 | 0 | 0 |
| Aug 24 | 4 | 0 | 0 | 0 |
| Sep 24 | 8 | 0 | 0 | 0 |
| Oct 24 | 2 | 0 | 0 | 0 |
| Nov 24 | 4 | 0 | 0 | 0 |
| Dec 24 | 1 | 0 | 0 | 0 |
| Jan 25 | 5 | 0 | 0 | 0 |
| Feb 25 | 4 | 0 | 0 | 0 |
| Mar 25 | 2 | 0 | 0 | 0 |
| Apr 25 | 6 | 0 | 0 | 0 |
| May 25 | 4 | 0 | 0 | 0 |
| Jun 25 | 5 | 0 | 0 | 0 |
| Jul 25 | 6 | 0 | 0 | 0 |
| Aug 25 | 5 | 0 | 0 | 0 |
| Sep 25 | 132 | 0 | 0 | 0 |
| Oct 25 | 18 | 0 | 0 | 0 |
| Nov 25 | 9 | 0 | 0 | 0 |
| Dec 25 | 14 | 0 | 0 | 0 |
| Jan 26 | 2 | 0 | 0 | 0 |
| Feb 26 | 13 | 0 | 0 | 0 |
| Mar 26 | 6 | 0 | 0 | 0 |
| Apr 26 | 13 | 0 | 0 | 0 |
| May 26 | 6 | 0 | 0 | 0 |
| Jun 26 | 16 | 0 | 0 | 0 |
| Jul 26 | 16 | 0 | 0 | 0 |
| Aug 26 | 11 | 0 | 0 | 0 |
| Sep 26 | 11 | 1 | 0 | 0 |
| Oct 26 | 7 | 1 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Abbott34
1 more in this ranking with a free account
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- False Positive Result69
- False Negative Result48
- Non Reproducible Results19
6 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions126
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1479-2024 · Started Mar 4, 2024 · Posted by FDA Apr 4, 2024
Reason given: Customer complaints were received regarding falsely elevated results for some patient samples. Internal studies with customer return samples confirmed potential interactions that may lead to falsely elevated results when processed as below on the same instrument: " ARCHITECT Syphilis TP (LN 8D06) and/or ARCHITECT...
Cause as FDA categorized it: Device Design
- Alinity i Anti-HCV Reagent Kit, List Number 08P0521Open, Classified
Z-1480-2024 · Started Mar 4, 2024 · Posted by FDA Apr 4, 2024
Reason given: Customer complaints were received regarding falsely elevated results for some patient samples. Internal studies with customer return samples confirmed potential interactions that may lead to falsely elevated results when processed as below on the same instrument: " ARCHITECT Syphilis TP (LN 8D06) and/or ARCHITECT...
Cause as FDA categorized it: Device Design
Z-1509-2016 · Started Jan 15, 2016
Reason given: OraSure Technologies, Inc. discovered the package insert included with the OraQuick HCV Rapid Antibody test Visual Reference Panel may be incorrect due to a complaint received from one of their customers. The customer reported they received the Ora Quick Ebola Visual Reference Panel instead of an OraQuick HCV Visual...
Cause as FDA categorized it: Unknown/Undetermined by firm
4 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.